TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD Cowen

TransMedics Group (NASDAQ:TMDX) had its price target trimmed by TD Cowen from $175.00 to $120.00 in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

TMDX has been the topic of a number of other research reports. Needham & Company LLC cut their price target on TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Oppenheimer reduced their price target on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Piper Sandler reissued an “overweight” rating and set a $180.00 price target on shares of TransMedics Group in a report on Tuesday, October 29th. Robert W. Baird reduced their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Finally, Stephens raised their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $139.30.

TransMedics Group Trading Up 0.6 %

NASDAQ:TMDX opened at $80.93 on Monday. The firm has a market capitalization of $2.72 billion, a P/E ratio of 85.88 and a beta of 2.08. The business has a 50 day simple moving average of $125.63 and a 200 day simple moving average of $139.55. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group has a 12-month low of $66.76 and a 12-month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same period last year, the firm posted ($0.12) EPS. The business’s revenue was up 63.7% compared to the same quarter last year. Equities research analysts predict that TransMedics Group will post 1.07 EPS for the current year.

Insider Buying and Selling

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,958 shares of company stock worth $5,230,528 in the last ninety days. 7.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently bought and sold shares of the stock. Neo Ivy Capital Management purchased a new stake in TransMedics Group during the third quarter valued at about $554,000. Geode Capital Management LLC raised its holdings in shares of TransMedics Group by 1.3% during the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after acquiring an additional 10,106 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of TransMedics Group in the 3rd quarter valued at approximately $368,000. MML Investors Services LLC boosted its stake in TransMedics Group by 140.3% in the 3rd quarter. MML Investors Services LLC now owns 4,123 shares of the company’s stock worth $647,000 after purchasing an additional 2,407 shares during the period. Finally, Zacks Investment Management acquired a new position in TransMedics Group in the 3rd quarter worth approximately $1,607,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.